CLX

Business Profile & Competitive Position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, reporting fiscal 2026 net sales of $6.7 billion with roughly 9,200 employees across approximately 25 countries and selling into about 95 markets. Its consumer brand portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt's Bees, while the professional arm markets Purell, CloroxPro, and Clorox Healthcare.

A net margin of 8.7% is consistent with a mature packaged-goods operator and a portfolio of category-leading-name brands, but it does not suggest an unusually wide economic moat. The more striking figure is the return on equity of -1,893.5%. ROE is normally used to gauge how efficiently a company generates profit from shareholders' equity, and a reading of this magnitude signals a deeply negative equity base rather than merely low profitability. Paired with positive net income, that usually indicates cumulative balance-sheet events—major share repurchases, write-downs, or accumulated losses—that have eroded book value below zero. Once equity turns negative, ROE becomes mathematically distorted and tells investors more about historical capital structure choices than about current competitive strength. The 8.7% net margin and the company's market position in household essentials are therefore the more reliable lenses for judging operating performance.

Financial Posture

Clorox currently carries a market capitalization of $10.7 billion and trades at a price-to-earnings ratio of 18.4. That multiple places it in the middle of the consumer-staples range, neither deep-value nor premium. The stock's beta is 0.54, consistent with a defensive, low-volatility business whose cash flows tend to move less dramatically than the broad market.

The negative ROE of -1,893.5% is the balance-sheet anomaly that dominates any financial snapshot. Combined with a positive P/E and a positive net margin, the disconnect confirms that earnings are being generated against a negative or negligible equity denominator. Analysts evaluating solvency and leverage should look past ROE and focus on debt levels, interest coverage, free cash flow, and the path back to positive book value. At the current price of $88.795, the stock sits below its 50-day exponential moving average of $98.11, and the RSI reading of 27.2 indicates technically oversold conditions. Those price metrics describe short-term sentiment, not underlying value.

Strategic Priorities & Outlook

Clorox's most recent 10-K frames its near-term agenda around the IGNITE strategy, which emphasizes four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. The operational backbone of that plan is a new enterprise resource planning (ERP) system paired with a broader digital transformation aimed at generating long-term efficiencies across the supply chain, digital commerce, innovation, and brand building.

Fiscal 2026 was a transitional year. Organic sales and earnings declined, and diluted EPS fell 26%, partly because macroeconomic headwinds and ERP transition timing had pulled some sales into fiscal 2025. The company is also reshaping its portfolio. In April 2026, it completed the acquisition of GOJO Industries, expanding its health and hygiene offerings and strengthening its business-to-business presence. Integrating GOJO and growing professional and institutional markets are now explicit priorities.

There are also structural customer and partnership shifts to watch. Walmart accounted for 26% of consolidated FY2026 net sales, while the five largest customers represented roughly half of consolidated net sales. That concentration gives large retailers significant negotiating leverage. Separately, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026; Clorox bought P&G's 20% interest, and Glad retained core intellectual property licenses on a royalty-free basis. The long-run economics of that change will depend on whether full ownership of Glad offsets the loss of P&G's backing in manufacturing and distribution.

Macro & Geopolitical Exposure

As a Household & Personal Products company, Clorox sits in a corner of Consumer Defensive that is relatively insulated from cyclical demand swings but highly exposed to input-cost volatility and retail-channel dynamics. The industry's raw-material base includes chemicals, resins, plastics, pulp-based packaging, and agricultural commodities. Movements in oil and natural-gas prices flow through to resin and chemical costs, while freight, labor, and packaging inflation can compress margins even when end-demand is stable.

Currency exposure matters too. With sales in roughly 95 markets and operations in about 25 countries, a stronger U.S. dollar reduces the translated value of overseas revenue and can create reported-sales headwinds. On the regulatory side, household and personal-care products face oversight from agencies such as the EPA and FDA in the United States, along with evolving chemical-safety and packaging rules in Europe and other jurisdictions. Trade policy can also move the needle: tariffs on imported raw materials or packaging raise landed costs, while any shift in trade agreements can affect both sourcing and export competitiveness. Finally, the industry is characterized by intense competition from private-label alternatives; when consumers trade down, national brands can lose volume unless innovation and marketing justify a price premium.

Recent Developments

Several recent headlines capture how the market is currently pricing Clorox. On September 14, 2026, defenseworld.net reported that NewEdge Advisors LLC had acquired shares of The Clorox Company. On September 9, 2026, Seeking Alpha published the transcript of Clorox's presentation at the Barclays 19th Annual Global Consumer Staples Conference, giving investors direct access to management's commentary on margins, brand investment, and the integration roadmap. The same day, 247wallst.com included Clorox among five well-known high-yield stocks that passive-income investors were buying near 52-week lows, highlighting the dividend-oriented narrative that often surrounds mature staples names. Earlier, on September 3, 2026, Zacks asked whether cost savings could offset inflation and protect Clorox's margins, reflecting the central debate around the stock: whether efficiency programs can keep profitability intact while the top line recovers.

Earnings Behavior & Post-Earnings Drift

Clorox has a solid recent record of exceeding the market's real expectation. Over the last eight reported quarters, it beat earnings estimates six times, for a beat rate of 75%, with an average earnings surprise of 9.6%. However, beats have not always translated into immediate rallies. The average 5-day price move following earnings across those quarters is 1.67%, classified as an upward drift, but the path has been uneven.

The most recent quarter, reported August 3, 2026, delivered actual EPS of $1.66 against an estimate of $1.64, a 1.2% surprise. The stock rose 6.52% the next day and 9.61% over the following five sessions. The prior quarter, April 30, 2026, showed a stronger beat—actual EPS of $1.64 versus $1.55, a 5.8% surprise—but the market sold the stock down 9.67% the next day and 4.49% over the next five sessions. The February 3, 2026 quarter was a miss: actual EPS of $1.39 versus $1.43, a 2.8% shortfall, yet the stock climbed 2.43% the next day and 5.63% over five days. The November 3, 2025 quarter, a 3.9% beat, produced a 1.17% next-day gain but a 4.08% five-day decline.

This pattern suggests that investors are reacting less to the binary beat or miss and more to the qualitative guidance around margins, ERP disruption, and integration expenses. For the next report, scheduled for November 3, 2026 after the close, the unofficial consensus stands at $1.11.

For a deeper dive into how institutional analysts are weighing Clorox's balance-sheet risks, margin recovery path, and GOJO integration, consult the full institutional verdict on the company's earnings and valuation metrics.